Suppression of macrophage activation with CNI-1493 increases survival in infant rats with systemic Haemophilus influenzae infection
2000 (English)In: Infection and Immunity, ISSN 0019-9567, E-ISSN 1098-5522, Vol. 68, no 9, 5329-5334 p.Article in journal (Refereed) Published
CNI-1493, a potent macrophage deactivator, was used to treat infant rats systemically infected with Haemophilus influenzae type b (Hib). CNI-1493 was injected 1 h prior to bacterial inoculation and 24 h later and resulted in a 75 percent increased rate of survival compared to that for untreated controls. The effect of CNI-1493 on the inflammatory response was studied by immunohistochemical detection of individual tumor necrosis factor alpha (TNF-α)-, interleukin 1 beta (IL-1β)-, and gamma interferon (IFN-γ)-producing cells in the spleen. A significant reduction of the incidence of TNF-α- and IL-1β-expressing cells was found for CNI-1493-treated animals. IFN-γ expression was not suppressed by CNI-1493, indicating that cytokine inhibition was specific in macrophages. CNI-1493 significantly reduced the number of infiltrating granulocytes in the brain from that for controls. This study provides evidence that CNI-1493 protects against lethal Hib infection by deactivating the inflammatory cascade in infant rats.
Place, publisher, year, edition, pages
2000. Vol. 68, no 9, 5329-5334 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-81948DOI: 10.1128/IAI.68.9.5329-5334.2000OAI: oai:DiVA.org:liu-81948DiVA: diva2:556759